127 related articles for article (PubMed ID: 22720245)
1. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
van Luijn MM; Chamuleau ME; Ossenkoppele GJ; van de Loosdrecht AA; Marieke van Ham S
Oncoimmunology; 2012 Mar; 1(2):211-213. PubMed ID: 22720245
[TBL] [Abstract][Full Text] [Related]
2. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
3. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
4. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
van Luijn MM; van de Loosdrecht AA; Lampen MH; van Veelen PA; Zevenbergen A; Kester MG; de Ru AH; Ossenkoppele GJ; van Hall T; van Ham SM
PLoS One; 2012; 7(4):e34649. PubMed ID: 22563374
[TBL] [Abstract][Full Text] [Related]
5. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Chamuleau ME; Souwer Y; Van Ham SM; Zevenbergen A; Westers TM; Berkhof J; Meijer CJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Res; 2004 Aug; 64(16):5546-50. PubMed ID: 15313888
[TBL] [Abstract][Full Text] [Related]
6. Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.
van Luijn MM; van den Ancker W; van Ham SM; van de Loosdrecht AA
Oncoimmunology; 2014 Dec; 3(12):e941737. PubMed ID: 25964856
[TBL] [Abstract][Full Text] [Related]
7. High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.
van den Ancker W; van Luijn MM; Chamuleau ME; Kelder A; Feller N; Terwijn M; Zevenbergen A; Schuurhuis GJ; van Ham SM; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Leuk Res; 2014 Jun; 38(6):691-3. PubMed ID: 24731748
[TBL] [Abstract][Full Text] [Related]
8. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
van Luijn MM; Chamuleau ME; Ressing ME; Wiertz EJ; Ostrand-Rosenberg S; Souwer Y; Zevenbergen A; Ossenkoppele GJ; van de Loosdrecht AA; van Ham SM
Cancer Immunol Immunother; 2010 Dec; 59(12):1825-38. PubMed ID: 20820776
[TBL] [Abstract][Full Text] [Related]
9. Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
van Luijn MM; Westers TM; Chamuleau ME; van Ham SM; Ossenkoppele GJ; van de Loosdrecht AA
Am J Pathol; 2011 Nov; 179(5):2157-61. PubMed ID: 21907692
[TBL] [Abstract][Full Text] [Related]
10. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
11. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
12. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
13. Differential up-regulation of HLA-DM, invariant chain, and CD83 on myeloid and plasmacytoid dendritic cells from peripheral blood.
Gómez J; Borràs FE; Singh R; Rajananthanan P; English N; Knight SC; Navarrete CV
Tissue Antigens; 2004 Feb; 63(2):149-57. PubMed ID: 14705986
[TBL] [Abstract][Full Text] [Related]
14. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.
van Luijn MM; van den Ancker W; Chamuleau ME; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Immunotherapy; 2010 Jan; 2(1):85-97. PubMed ID: 20635891
[TBL] [Abstract][Full Text] [Related]
15. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
16. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
Mutis T; Schrama E; Melief CJ; Goulmy E
Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
[TBL] [Abstract][Full Text] [Related]
17. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
18. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
[TBL] [Abstract][Full Text] [Related]
19. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses.
Chaturvedi P; Hengeveld R; Zechel MA; Lee-Chan E; Singh B
Int Immunol; 2000 Jun; 12(6):757-65. PubMed ID: 10837403
[TBL] [Abstract][Full Text] [Related]
20. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
